Biological determinants of health disparities in multiple myeloma

Blood Cancer Journal

Volumn 8, Issue 9, 2018, Pages

  Smith, Cheryl Jacobs ^a   Ambs, Stefan ^a   Landgren, Ola ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN; CANCER SURVIVAL; EUROPEAN; GAMMOPATHY; HEALTH DISPARITY; HUMAN; MULTIPLE MYELOMA; POPULATION DIFFERENTIATION; RACE DIFFERENCE; REVIEW; TREATMENT RESPONSE; DISEASE PREDISPOSITION; ETHNOLOGY; FEMALE; HEALTH SURVEY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; POPULATION GROUP; PREVALENCE; PROGNOSIS; STATISTICS AND NUMERICAL DATA;

DISEASE SUSCEPTIBILITY; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; MALE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; POPULATION GROUPS; POPULATION SURVEILLANCE; PREVALENCE; PROGNOSIS;

EID: 85053003106     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/s41408-018-0118-z     Document Type: Review

References (48)

1. Benjamin, M., Reddy, S. & Brawley, O. W. Myeloma and race: a review of the literature. Cancer Metastas. Rev. 22, 87–93 (2003)
2. Howlader N. N. A., et al. SEER Cancer Statistics Review, 1975–2014. 2017; based on November 2016 SEER data submission
3. Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412–5417 (2009)
4. Weiss, B. M., Abadie, J., Verma, P., Howard, R. S. & Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113, 5418–5422 (2009)
5. Weiss, B. M. et al. Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients. Am. J. Hematol. 86, 475–478 (2011)
6. Kyle, R. A. & Rajkumar, S. V. Epidemiology of the plasma-cell disorders. Best Pract. Res. Clin. Haematol. 20, 637–664 (2007)
7. Alexander, D. D. et al. Multiple myeloma: a review of the epidemiologic literature. Int. J. Cancer 120(Suppl 12), 40–61 (2007)
8. McFarlane, H. Multiple myeloma in Jamaica: a study of 40 cases with special reference to the incidence and laboratory diagnosis. J. Clin. Pathol. 19, 268–271 (1966)
9. Talerman, A. Clinico-pathological study of multiple myeloma in Jamaica. Br. J. Cancer 23, 285–293 (1969)
10. McFarlane, H., Talerman, A. & Steinberg, A. G. Immunoglobulins in Jamaicans and Nigerians with immunogenetic typing of myeloma and lymphoma in Jamaicans. J. Clin. Pathol. 23, 124–126 (1970)
11. Brown, L. M., Gridley, G., Check, D. & Landgren, O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111, 3388–3394 (2008)
12. Landgren, O. & Weiss, B. M. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 23, 1691–1697 (2009)
13. Greenberg, A. J., Vachon, C. M. & Rajkumar, S. V. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia 26, 609–614 (2012)
14. Baker, A. et al. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood 121, 3147–3152 (2013)
15. Landgren, O. et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin. Proc. 82, 1468–1473 (2007)
16. Landgren, O. et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia 28, 1537–1542 (2014)
17. Soderberg, K. C., Hagmar, L., Schwartzbaum, J. & Feychting, M. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health 4, 51 (2004)
18. Kristinsson, S. Y. et al. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica 94, 1581–1589 (2009)
19. Dosani, T., Carlsten, M., Maric, I. & Landgren, O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J. 5, e321 (2015)
20. Rajkumar, S. V., Kyle, R. A. & Buadi, F. K. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin. Proc. 85, 945–948 (2010)
21. Zingone, A. & Kuehl, W. M. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin. Hematol. 48, 4–12 (2011)
22. Cohen, H. J., Crawford, J., Rao, M. K., Pieper, C. F. & Currie, M. S. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am. J. Med. 104, 439–444 (1998)
23. Landgren, O. et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107, 904–906 (2006)
24. Landgren, O. et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J. 7, e618 (2017)
25. Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362–1369 (2006)
26. Jain, M., Ascensao, J. & Schechter, G. P. Familial myeloma and monoclonal gammopathy: a report of eight African American families. Am. J. Hematol. 84, 34–38 (2009)
27. Gragert, L. et al. Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations. Blood 124, 2657–2665 (2014)
28. Beksac, M. et al. HLA polymorphism and risk of multiple myeloma. Leukemia 30, 2260–2264 (2016)
29. Prokunina-Olsson, L. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164–171 (2013)
30. Aka, P. V. et al. Association of the IFNL4-DeltaG allele with impaired spontaneous clearance of hepatitis C virus. J. Infect. Dis. 209, 350–354 (2014)
31. Pulte, D., Redaniel, M. T., Brenner, H., Jansen, L. & Jeffreys, M. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leuk. Lymphoma 55, 1083–1089 (2014)
32. Waxman, A. J. et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116, 5501–5506 (2010)
33. Fast Stats: An interactive tool for access to SEER cancer statistics
34. Greenberg, A. J. et al. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer J. 5, e271 (2015)
35. Manojlovic, Z. et al. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases. PLoS Genet. 13, e1007087 (2017)
36. Wallace, T. A. et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 68, 927–936 (2008)
37. Powell, I. J. et al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomark Prev 22, 891–897 (2013)
38. Rose, A. E. et al. Copy number and gene expression differences between African American and Caucasian American prostate cancer. J. Transl. Med. 8, 70 (2010)
39. Hardiman, G. et al. Systems analysis of the prostate transcriptome in African-American men compared with European-American men. Pharmacogenomics 17, 1129–1143 (2016)
40. Reis, B. S. et al. Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clin. Cancer Res. 19, 6112–6125 (2013)
41. Goering, W., Ribarska, T. & Schulz, W. A. Selective changes of retroelement expression in human prostate cancer. Carcinogenesis 32, 1484–1492 (2011)
42. Pérot P. et al. Microarray-based identification of individual HERV loci expression: application to biomarker discovery in prostate cancer. J Vis Exp. e50713 (2013). 10.3791/50713
43. Wallace, T. A. et al. Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers. Carcinogenesis 35, 2074–2083 (2014)
44. Macfarlane, C. & Simmonds, P. Allelic variation of HERV-K(HML-2) endogenous retroviral elements in human populations. J. Mol. Evol. 59, 642–656 (2004)
45. Jha, A. R. et al. Cross-sectional dating of novel haplotypes of HERV-K 113 and HERV-K 115 indicate these proviruses originated in Africa before Homo sapiens. Mol. Biol. Evol. 26, 2617–2626 (2009)
46. Smith, C. J. et al. Aspirin use reduces the risk of aggressive prostate cancer and disease recurrence in African-American men. Oncology 26, 845–853 (2017)
47. Buadi, F. et al. High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa. Am. J. Hematol. 86, 554–558 (2011)
48. Idelman, G. et al. Functional profiling of uncommon VCAM1 promoter polymorphisms prevalent in African American populations. Hum. Mutat. 28, 824–829 (2007)